Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

51.9K
Overview
51.9K
Harmonic Mean01:09

Harmonic Mean

3.8K
The arithmetic mean is usually skewed towards the larger values in the data set. Therefore, to avoid this inherent bias towards smaller values, the harmonic mean is used.
Take the example of the speed of a car, which is the measure of the rate of distance traveled. If the vehicle traverses the same distance back-and-forth, its average speed equals the total distance traveled divided by the total time taken. However, if the car moves with varying speeds, then the arithmetic mean is more skewed...
3.8K
Simple Harmonic Motion01:21

Simple Harmonic Motion

15.4K
Simple harmonic motion is the name given to oscillatory motion for a system where the net force can be described by Hooke's law. If the net force can be described by Hooke's law and there is no damping (by friction or other non-conservative forces), then a simple harmonic oscillator will oscillate with equal displacement on either side of the equilibrium position. To derive an equation for period and frequency, the equation of motion is used. The period of a simple harmonic oscillator is given...
15.4K
Energy in Simple Harmonic Motion01:23

Energy in Simple Harmonic Motion

13.0K
To determine the energy of a simple harmonic oscillator, consider all the forms of energy it can have during its simple harmonic motion. According to Hooke's Law, the energy stored during the compression/stretching of a string in a simple harmonic oscillator is potential energy. As the simple harmonic oscillator has no dissipative forces, it also possesses kinetic energy. In the presence of conservative forces, both energies can interconvert during oscillation, but the total energy remains...
13.0K
Cancer Vaccines01:30

Cancer Vaccines

1.1K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.1K
Characteristics of Simple Harmonic Motion01:17

Characteristics of Simple Harmonic Motion

18.1K
The key characteristic of the simple harmonic motion is that the acceleration of the system and, therefore, the net force are proportional to the displacement and act in the opposite direction to the displacement. Additionally, the period and frequency of a simple harmonic oscillator are independent of its amplitude. For example, diving boards move faster or slower based on their thickness. A stiff, thick diving board has a large force constant, which causes it to have a smaller period, while a...
18.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From Global Insights to Local Action: Bridging Vaccine Design and Manufacturing Gaps in H5N1 Pandemic Readiness.

Vaccines·2026
Same author

Safety and immunogenicity of a booster dose of COVAC-2, a Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in previously vaccinated healthy adults; a randomized controlled multicentre trial.

Human vaccines & immunotherapeutics·2026
Same author

Unpacking the mRNA Supply Chain: Challenges and Opportunities for Global Health.

Vaccines·2026
Same author

Toll-like receptor 5 agonist is a potent adjuvant for intradermal vaccination.

Vaccine·2026
Same author

Pathways to economically viable and sustainable vaccine manufacturing in LMICs.

Vaccine·2026
Same author

Safety and immunogenicity of COVAC-2, a Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in healthy adults; a randomized controlled first-in-human dose-escalation trial.

Vaccine·2025
Same journal

Inflammatory responses in HIV-1 genetic subtypes in relationship with anti-retroviral drug resistance in Minna, Niger State, North Central Nigeria.

BMC immunology·2026
Same journal

IL-17A and IFN-α associated with female genital schistosomiasis lesions.

BMC immunology·2026
Same journal

Hsa_circ_0077658 serves as a potential diagnostic biomarker for severe pneumonia in children and alleviates lipopolysaccharide-induced damage to bronchial epithelial cells by modulating the miR-15a-5p/NF1 axis.

BMC immunology·2026
Same journal

Cytokine and chemokine signatures of steady-state sickle cell disease in African children: a cross-sectional study.

BMC immunology·2026
Same journal

Clinical and immunological factors associated with gastrointestinal involvement in common variable immunodeficiency: a real-world study.

BMC immunology·2026
Same journal

MicroRNA-18a-3p as a biomarker for neonatal respiratory distress syndrome and its effects in alveolar epithelial type II cells.

BMC immunology·2026
See all related articles

Related Experiment Video

Updated: Feb 15, 2026

In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D
08:15

In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D

Published on: December 9, 2022

2.3K

Down selecting adjuvanted vaccine formulations: a comparative method for harmonized evaluation.

Sumera Y Younis1, Christophe Barnier-Quer2, Simon Heuking2

  • 1Biomedical Primate Research Centre, Department of Parasitology, Rijswijk, The Netherlands.

BMC Immunology
|February 2, 2018
PubMed
Summary
This summary is machine-generated.

This study introduces a harmonized method for comparing vaccine formulations, using reference antigens and adjuvants to benchmark immunogenicity and guide development. This approach aids in selecting optimal antigen/adjuvant combinations for effective vaccine design.

Keywords:
AMA1AdjuvantsAg85AAluminium oxyhydroxideHBsAgHepatitis BPlasmodium falciparumQS21Squalene-in-water SWETuberculosis

More Related Videos

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection
07:32

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection

Published on: September 1, 2023

2.4K
Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
12:53

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

2.2K

Related Experiment Videos

Last Updated: Feb 15, 2026

In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D
08:15

In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D

Published on: December 9, 2022

2.3K
Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection
07:32

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection

Published on: September 1, 2023

2.4K
Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
12:53

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

2.2K

Area of Science:

  • Vaccinology
  • Immunology
  • Biotechnology

Background:

  • Modern vaccine development faces challenges in comparing numerous adjuvanted formulations.
  • A harmonized method is needed for efficient antigen/adjuvant combination assessment.
  • Reference antigens and adjuvants can serve as benchmarks for vaccine studies.

Purpose of the Study:

  • To describe a method for harmonized comparison of antigen/adjuvant vaccine formulations.
  • To establish benchmarks for vaccine development using model antigens and adjuvants.
  • To facilitate rational down-selection of vaccine candidates.

Main Methods:

  • Selected three reference antigens (AMA1, HBsAg, Ag85A) and three adjuvants (aluminium oxyhydroxide, squalene-in-water emulsion, QS21 liposome).
  • Formulated nine antigen/adjuvant combinations and assessed stability and immunogenicity in mice.
  • Analyzed cellular immune responses (IFN-γ, IL-5) via ELISPOT and humoral responses (total IgG, IgG1, IgG2b, IgG2c) via ELISA.

Main Results:

  • Nine antigen/adjuvant formulations were created and evaluated in mice.
  • Immunogenicity data (cellular and humoral) were collected for each formulation.
  • Stability and immune response profiles were established as benchmarks.

Conclusions:

  • The study provides reference antigens and adjuvants spanning diverse immune responses.
  • The described harmonized methodology can be utilized for adjuvant/antigen comparison.
  • This approach supports rational decision-making in vaccine development.